The usual starting dose is 1 drop of 0.25% TIMOPTOL in the affected eye(s) twice a day. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5% solution in the affected eye(s) twice a day.
If needed, concomitant therapy with other agent(s) for lowering intraocular pressure may be given with TIMOPTOL. The use of 2 topical beta-adrenergic blocking agents is not recommended (see Precautions).
Since in some patients the pressure-lowering response to TIMOPTOL may require a few weeks to stabilize, evaluations should include a determination of intraocular pressure after approximately 4 weeks of treatment with TIMOPTOL.
If the intraocular pressure is maintained at satisfactory levels, many patients can be placed on once-a-day therapy.
When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in an increase in local activity.
How to Transfer Patients from Other Therapy: When a patient is transferred from another topical ophthalmic β-adrenergic blocking agent, that agent should be discontinued after proper dosing on one day and treatment with TIMOPTOL started on the following day with one drop of 0.25 percent TIMOPTOL in the affected eye twice a day. The dose may be increased to 1 drop of 0.5 percent TIMOPTOL twice a day if the clinical response is not adequate.
When a patient is transferred from a single antiglaucoma agent, other than a topical ophthalmic beta-adrenergic blocking agent, continue the agent already being used and add one drop of 0.25 percent TIMOPTOL in each affected eye twice a day. On the following day, discontinue the previously used antiglaucoma agent completely and continue with TIMOPTOL. If a higher dosage of TIMOPTOL is required, substitute one drop of 0.5 percent solution in each affected eye twice a day.
Use in Children: The usual starting dose is one drop of 0.25 percent TIMOPTOL in the affected eye(s) every 12 hours, in addition to other antiglaucoma medication. The dosage may be increased to one drop of 0.5 percent solution in the affected eye(s) every 12 hours, if necessary. The use of TIMOPTOL is not recommended in premature infants or neonates.
Preservative-Free Unit Dose: For patients who may be sensitive to the preservative benzalkonium chloride, or when use of a preservative-free topical medication is advisable, a formulation of TIMOPTOL without the preservative benzalkonium chloride is available. This formulation is packaged in individual unit dose containers of 2 strengths: 0.25% or 0.5%.
Preservative-Free Unit Dose TIMOPTOL is a sterile solution that does not contain preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since sterility cannot be maintained after the individual unit is opened, the remaining contents should be discarded immediately after administration.